A
Andrea Mortara
Researcher at University of Milan
Publications - 159
Citations - 10813
Andrea Mortara is an academic researcher from University of Milan. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 39, co-authored 142 publications receiving 9664 citations. Previous affiliations of Andrea Mortara include Research Medical Center.
Papers
More filters
Journal ArticleDOI
Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.
Ovidiu Chioncel,Marianna Adamo,Maria Nikolaou,John Parissis,Alexandre Mebazaa,Mehmet Yilmaz,Christian Hassager,Brenda Moura,Johann Bauersachs,Veli-Pekka Harjola,Elena-Laura Antohi,Tuvia Ben-Gal,Sean P. Collins,Vlad Anton Iliescu,Magdy Abdelhamid,Jelena Čelutkienė,Stamatis Adamopoulos,Lars Lund,Mariantonietta Cicoira,Josep Masip,Hadi Skouri,Finn Gustafsson,Amina Rakisheva,Ingo Ahrens,Andrea Mortara,Abdallah Almaghraby,Kevin Damman,Oscar Mascarilla Miró,K. Huber,Arsen C. Ristić,Loreena Hill,Wilfried Mullens,Alaide Chieffo,Jozef Bartunek,Pasquale Paolisso,Antoni Bayes-Genis,Stefan D. Anker,Susanna Price,Gerasimos Filippatos,Frank Ruschitzka,Petar M. Seferović,Rafael Vidal-Pérez,Alec Vahanian,Marco Metra,Theresa McDonagh,Emanuele Barbato,Andrew J.S. Coats,Giuseppe M.C. Rosano +47 more
TL;DR: In this paper , the authors describe the epidemiology, pathophysiology, and overall treatment approach for patients with VHD who present with acute heart failure (AHF) in the setting of VHD and AHF.
Journal ArticleDOI
SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction
TL;DR: This study investigates the eligibility of the EMPEROR-PRESERVED and DELIVER trial to a real-world heart failure population comparing the baseline characteristics of patients to the recruited patients of clinical trials and the difference between the characteristics of the HFpEF population and trials population.
Journal ArticleDOI
P288 treatment of heart failure in clinical practice: non–interventional observational study on patients with heart failure treated with dapagliflozin (evolution–hf italy)
Francesco Orso,Pietro Ameri,Stefano Carugo,Andrea Di Lenarda,Massimo Iacoviello,Ciro Indolfi,Andrea Mortara,Pasquale Perrone Filardi,M Volpe,Maurizio Volterrani,G. Rosano +10 more
TL;DR: The EVOLUTION-HF programme as discussed by the authors was designed to collect real-world data in 13 European Countries, including Italy, to characterize patients initiated on dapagliflozin for the treatment of heart failure and to estimate occurrence of treatment discontinuations.